|
Thermogenesis Holdings, Inc. (THMO) Valation DCF
US | Healthcare | Medical - Devices | PNK
|
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
ThermoGenesis Holdings, Inc. (THMO) Bundle
Évaluer Thermogenesis Holdings, Inc. (THMO) Perspectives financières comme un professionnel! Cette calculatrice DCF (THMO) propose des données financières pré-remplies et la flexibilité pour modifier la croissance des revenus, le WACC, les marges et d'autres hypothèses cruciales pour s'aligner sur vos projections.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 13.0 | 9.7 | 9.3 | 10.5 | 9.4 | 8.8 | 8.2 | 7.7 | 7.1 | 6.7 |
| Revenue Growth, % | 0 | -25.32 | -4.62 | 12.79 | -9.9 | -6.76 | -6.76 | -6.76 | -6.76 | -6.76 |
| EBITDA | -4.7 | -8.2 | -6.6 | -5.3 | -7.7 | -5.7 | -5.3 | -4.9 | -4.6 | -4.3 |
| EBITDA, % | -36.28 | -83.75 | -70.99 | -50.27 | -81.95 | -64.65 | -64.65 | -64.65 | -64.65 | -64.65 |
| Depreciation | .8 | .8 | .6 | .9 | 1.1 | .7 | .7 | .6 | .6 | .6 |
| Depreciation, % | 6.18 | 7.74 | 6.81 | 8.83 | 12.14 | 8.34 | 8.34 | 8.34 | 8.34 | 8.34 |
| EBIT | -5.5 | -8.9 | -7.2 | -6.2 | -8.9 | -6.4 | -6.0 | -5.6 | -5.2 | -4.9 |
| EBIT, % | -42.45 | -91.49 | -77.8 | -59.11 | -94.09 | -72.99 | -72.99 | -72.99 | -72.99 | -72.99 |
| Total Cash | 3.2 | 7.2 | 7.3 | 4.2 | 2.0 | 4.2 | 3.9 | 3.6 | 3.4 | 3.2 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 1.3 | 1.4 | .7 | 1.9 | .9 | 1.1 | 1.0 | .9 | .9 | .8 |
| Account Receivables, % | 9.8 | 14.18 | 7.89 | 17.79 | 10.05 | 11.94 | 11.94 | 11.94 | 11.94 | 11.94 |
| Inventories | 3.5 | 5.9 | 5.4 | 3.3 | 1.4 | 3.4 | 3.1 | 2.9 | 2.7 | 2.5 |
| Inventories, % | 26.7 | 60.31 | 57.81 | 31.8 | 14.89 | 38.3 | 38.3 | 38.3 | 38.3 | 38.3 |
| Accounts Payable | 1.4 | 1.4 | 1.3 | .8 | .9 | 1.0 | .9 | .9 | .8 | .8 |
| Accounts Payable, % | 11.09 | 14.02 | 13.77 | 7.82 | 10.04 | 11.35 | 11.35 | 11.35 | 11.35 | 11.35 |
| Capital Expenditure | -.2 | .0 | -.1 | -.4 | -1.7 | -.4 | -.4 | -.4 | -.4 | -.3 |
| Capital Expenditure, % | -1.39 | -0.23604 | -1 | -3.82 | -18.35 | -4.96 | -4.96 | -4.96 | -4.96 | -4.96 |
| Tax Rate, % | 4.99 | 4.99 | 4.99 | 4.99 | 4.99 | 4.99 | 4.99 | 4.99 | 4.99 | 4.99 |
| EBITAT | -5.2 | -8.7 | -6.9 | -5.9 | -8.4 | -6.1 | -5.7 | -5.3 | -5.0 | -4.6 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -7.9 | -10.5 | -5.3 | -4.9 | -6.1 | -7.9 | -5.2 | -4.9 | -4.5 | -4.2 |
| WACC, % | 89.37 | 92.43 | 91.02 | 90.67 | 90.29 | 90.76 | 90.76 | 90.76 | 90.76 | 90.76 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -6.8 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -4 | |||||||||
| Terminal Value | -5 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -7 | |||||||||
| Net Debt | 9 | |||||||||
| Equity Value | -16 | |||||||||
| Diluted Shares Outstanding, MM | 2 | |||||||||
| Equity Value Per Share | -6.55 |
What You Will Get
- Editable Excel Template: A fully customizable Excel-based DCF Calculator featuring pre-filled real THMO financials.
- Real-World Data: Access to historical data and forward-looking estimates (highlighted in the yellow cells).
- Forecast Flexibility: Adjust forecast assumptions such as revenue growth, EBITDA %, and WACC.
- Automatic Calculations: Instantly observe how your inputs affect ThermoGenesis Holdings’ valuation.
- Professional Tool: Designed for investors, CFOs, consultants, and financial analysts.
- User-Friendly Design: Organized for clarity and ease of use, complete with step-by-step instructions.
Key Features
- Comprehensive DCF Calculator: Features both unlevered and levered DCF valuation models tailored for ThermoGenesis Holdings, Inc. (THMO).
- WACC Calculator: A pre-configured Weighted Average Cost of Capital sheet with adjustable parameters.
- Customizable Forecast Assumptions: Adjust growth rates, capital expenditures, and discount rates to fit your analysis.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios specific to ThermoGenesis Holdings, Inc. (THMO).
- Interactive Dashboard and Charts: Visual representations that encapsulate key valuation metrics for straightforward analysis.
How It Works
- Download: Obtain the ready-to-use Excel file featuring ThermoGenesis Holdings, Inc. (THMO) financial data.
- Customize: Modify projections, including revenue growth, EBITDA %, and WACC.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Generate various forecasts and instantly compare results.
- Make Decisions: Leverage the valuation outcomes to inform your investment strategy.
Why Choose ThermoGenesis Holdings, Inc. (THMO)?
- Innovative Solutions: Benefit from advanced technologies in cell therapy and regenerative medicine.
- Proven Expertise: Backed by a team of professionals with extensive experience in the biotech industry.
- Commitment to Quality: Our products meet the highest standards for safety and efficacy.
- Customer-Centric Approach: We prioritize your needs and provide tailored support for all our clients.
- Industry Recognition: Trusted by leading institutions and researchers worldwide.
Who Should Use This Product?
- Healthcare Professionals: Understand advanced cellular therapies and their applications using real-world data.
- Researchers: Integrate cutting-edge technologies into studies or clinical trials.
- Investors: Evaluate your own strategies and assess the market potential for ThermoGenesis Holdings, Inc. (THMO).
- Biotech Analysts: Enhance your analysis with a comprehensive, customizable model for evaluating biotech companies.
- Entrepreneurs: Discover how established biotech firms like ThermoGenesis are positioned in the market.
What the Template Contains
- Pre-Filled Data: Includes ThermoGenesis Holdings, Inc.'s historical financials and forecasts.
- Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs.
- Key Financial Ratios: Analyze ThermoGenesis Holdings, Inc.'s profitability, efficiency, and leverage.
- Customizable Inputs: Edit revenue growth, margins, and tax rates with ease.
- Clear Dashboard: Charts and tables summarizing key valuation results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.